The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
Sponsor: Ever Neuro Pharma GmbH
Listed as NCT00868283, this PHASE4 trial focuses on Ischemic Stroke and remains completed. Sponsored by Ever Neuro Pharma GmbH, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jan 2024 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ever Neuro Pharma GmbH
- Excel PharmaStudies, Inc.
- idv Datenanalyse und Versuchsplanung
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anhui, China, Anshan, China, Baotou, China, Beijing, China, Changchun, China, Changsha, China, Chengdu, China, Chongqing, China, Dalian, China, Fuzhou, China and 16 more location s